Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0010 Transporter Info | ||||
| Gene Name | SLC22A1 | ||||
| Protein Name | Organic cation transporter 1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs12208357 | ||||
| Site of GPD | chr6:160122116 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>T | ||||
| Minor Allele Frequency | T=0.0204/102 (Global) | ||||
| Allele C | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Metformin | Drug Info | Diabetes Mellitus | Correlated with the increased drug bioavailability (AUC, CL & AUC/CL ratio) | [ 1] | |
| Allele T | Click to Show/Hide the Full List of Affected Drugs: 4 Drugs in Total | ||||
| Tramadol | Drug Info | Healthy Individuals | Correlated with the higher o-desmethyltramadol plasma concentrations in healthy individuals (compare with allele C) | [ 2] | |
| Metformin | Drug Info | Healthy Individuals | Correlated with the increased drug exposure in healthy individuals (compare with allele C) | [ 3] | |
| Metformin | Drug Info | Diabetes Mellitus | Irrelevant to the drug response in patients (compare with allele C) | [ 4] | |
| Metformin | Drug Info | Polycystic Ovary Syndrome | Irrelevant to the drug response in patients (compare with allele C) | [ 5] | |
| Genotype TT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Metformin | Drug Info | Healthy Individuals | Correlated with the decreased drug exposure in healthy individuals (compare with genotype CC) | [ 6] | |
| Genetic Polymorphism | rs2282143 | ||||
| Site of GPD | chr6:160136611 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>G / C>T | ||||
| Minor Allele Frequency | T=0.0663/332 (Global) | ||||
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Metformin | Drug Info | Healthy Individuals | Correlated with the increased drug clearance in healthy individuals (compare with Genotypes CT + TT) | [ 7] | |
| Genetic Polymorphism | rs35167514 | ||||
| Site of GPD | chr6:160139849 (GRCh38.p12) | ||||
| GPD Type | DeletionDeletion | ||||
| Allele(s) in dbSNP | delA | ||||
| Genotype DEL | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Tramadol | Drug Info | Healthy Individuals | Correlated with the increased plasma concentrations of o-desmethyltramadol in healthy individuals (compare with allele A) | [ 2] | |
| Genetic Polymorphism | rs36056065 | ||||
| Allele GTAAGTTG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Metformin | Drug Info | Diabetes Mellitus | Correlated with the gastrointestinal side effects in patients (compare with allele del) | [ 8] | |
| Genetic Polymorphism | rs628031 | ||||
| Site of GPD | chr6:160139813 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | A>C / A>G | ||||
| Minor Allele Frequency | A=0.3123/1564 (Global) | ||||
| Allele A | Click to Show/Hide the Full List of Affected Drugs: 2 Drugs in Total | ||||
| Metformin | Drug Info | Diabetes Mellitus | Correlated with the decreased drug response in patients (compare with allele G); Correlated with the gastrointestinal toxicity in patients (compare with allele G) | [ 8], [ 10] | |
| Lamotrigine | Drug Info | Epilepsy | Irrelevant to the drug response in patients (compare with Allele G) | [ 11] | |
| Genotype GG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Lamotrigine | Drug Info | Epilepsy | Correlated with the increased drug dose in patients (compare with genotypes AA + AG) | [ 11] | |
| Genotypes AA + AG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Lamotrigine | Drug Info | Epilepsy | Correlated with the increased drug concentrations in patients (compare with genotype GG) | [ 10] | |
| Genetic Polymorphism | rs683369 | ||||
| Site of GPD | chr6:160130172 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>A / G>C / G>T | ||||
| Minor Allele Frequency | G=0.1238/620 (Global) | ||||
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Imatinib | Drug Info | Bcr-Abl Positive Chronic Myelogenous Leukemia | Correlated with the decreased drug concentrations in patients (compare with genotypes CG + GG); Correlated with the increased drug clearance in patients (compare with genotypes CG + GG) | [ 12] | |
| Genotypes CG + GG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Imatinib | Drug Info | Gastrointestinal Stromal Tumors | Correlated with the increased conjunctival hemorrhage risk in patients (compare with genotype CC) | [ 13] | |
| Genetic Polymorphism | rs72552763 | ||||
| Site of GPD | chr6:160139849-160139853 (GRCh38.p12) | ||||
| GPD Type | Indel Insertion and Deletion | ||||
| Allele(s) in dbSNP | delGAT | ||||
| Genotype GAT/DEL | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Metformin | Drug Info | Diabetes Mellitus | Correlated with the decreased drug trough steady-state concentration in patients (compare with genotype GAt/GAt) | [ 14] | |
| Genetic Polymorphism | rs594709 | ||||
| Site of GPD | chr6:160134722 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>A | ||||
| Minor Allele Frequency | G=0.3179/1592 (Global) | ||||
| Genotypes AA + AG | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Metformin | Drug Info | Diabetes Mellitus | Correlated with the increased drug response in patients (compare with genotype GG) | [ 15] | |
| References | |||||
| 1 | Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008 Feb;83(2):273-80. | ||||
| 2 | Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther. 2011 Jul;90(1):143-50. | ||||
| 3 | Influence of pharmacogenetic polymorphisms and demographic variables on metformin pharmacokinetics in an admixed Brazilian cohort. Br J Clin Pharmacol. 2018 May;84(5):987-996. | ||||
| 4 | Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis. Clin Pharmacol Ther. 2017 Jun;101(6):763-772. | ||||
| 5 | The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. Basic Clin Pharmacol Toxicol. 2018 Feb;122(2):239-244. | ||||
| 6 | Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans. Clin Pharmacol Ther. 2017 Nov;102(5):841-848. | ||||
| 7 | Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. AAPS J. 2013 Apr;15(2):571-80. | ||||
| 8 | Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics. 2012 Sep;22(9):659-66. | ||||
| 9 | Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2007;52(2):117-22. | ||||
| 10 | Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. Epilepsy Res. 2016 Nov;127:186-190. | ||||
| 11 | Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. Br J Clin Pharmacol. 2016 Aug;82(2):399-411. | ||||
| 12 | The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J. 2014 Aug;14(4):328-35. | ||||
| 13 | Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J. 2018 May 22;18(3):460-466. | ||||
| 14 | The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011 Dec;21(12):837-50. | ||||
| 15 | The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.